543 related articles for article (PubMed ID: 23607863)
1. Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections.
Günther G; Dreger B
Microbiol Immunol; 2013 Jul; 57(7):527-35. PubMed ID: 23607863
[TBL] [Abstract][Full Text] [Related]
2. Pneumococcal antibody levels in children with PID receiving immunoglobulin.
Tuerlinckx D; Florkin B; Ferster A; De Schutter I; Chantrain C; Haerynck F; Philippet P; Strengers P; Laub R
Pediatrics; 2014 Jan; 133(1):e154-62. PubMed ID: 24366995
[TBL] [Abstract][Full Text] [Related]
3. Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases.
Dashti-Khavidaki S; Aghamohammadi A; Farshadi F; Movahedi M; Parvaneh N; Pouladi N; Moazzami K; Cheraghi T; Mahdaviani SA; Saghafi S; Heydari G; Abdollahzade S; Rezaei N
J Investig Allergol Clin Immunol; 2009; 19(2):139-45. PubMed ID: 19476018
[TBL] [Abstract][Full Text] [Related]
4. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G.
Berger M; Murphy E; Riley P; Bergman GE;
South Med J; 2010 Sep; 103(9):856-63. PubMed ID: 20689467
[TBL] [Abstract][Full Text] [Related]
5. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies.
Orange JS; Grossman WJ; Navickis RJ; Wilkes MM
Clin Immunol; 2010 Oct; 137(1):21-30. PubMed ID: 20675197
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura.
van der Meer JW; van Beem RT; Robak T; Deptala A; Strengers PF
Vox Sang; 2011 Aug; 101(2):138-46. PubMed ID: 21749402
[TBL] [Abstract][Full Text] [Related]
7. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study.
Molica S; Musto P; Chiurazzi F; Specchia G; Brugiatelli M; Cicoira L; Levato D; Nobile F; Carotenuto M; Liso V; Rotoli B
Haematologica; 1996; 81(2):121-6. PubMed ID: 8641639
[TBL] [Abstract][Full Text] [Related]
8. A multicentre, prospective, non-randomized, sequential, open-label trial to demonstrate the bioequivalence between intravenous immunoglobulin new generation (IGNG) and standard IV immunoglobulin (IVIG) in adult patients with primary immunodeficiency (PID).
Viallard JF; Brion JP; Malphettes M; Durieu I; Gardembas M; Schleinitz N; Hoarau C; Lazaro E; Puget S
Rev Med Interne; 2017 Sep; 38(9):578-584. PubMed ID: 28683953
[TBL] [Abstract][Full Text] [Related]
9. Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions.
Bichuetti-Silva DC; Furlan FP; Nobre FA; Pereira CT; Gonçalves TR; Gouveia-Pereira M; Rota R; Tavares L; Mazzucchelli JT; Costa-Carvalho BT
Int Immunopharmacol; 2014 Dec; 23(2):442-6. PubMed ID: 25257732
[TBL] [Abstract][Full Text] [Related]
10. Early intravenous immunoglobulin replacement in hypogammaglobulinemic heart transplant recipients: results of a clinical trial.
Sarmiento E; Diez P; Arraya M; Jaramillo M; Calahorra L; Fernandez-Yañez J; Palomo J; Sousa I; Hortal J; Barrio J; Alonso R; Muñoz P; Navarro J; Vicario J; Fernandez-Cruz E; Carbone J
Transpl Infect Dis; 2016 Dec; 18(6):832-843. PubMed ID: 27639067
[TBL] [Abstract][Full Text] [Related]
11. A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency.
Visentin A; Molinari MC; Pravato S; Cellini A; Angotzi F; Cavaretta CA; Ruocco V; Imbergamo S; Piazza F; Proietti G; Mauro FR; Trentin L
Curr Oncol; 2022 Dec; 30(1):274-283. PubMed ID: 36661671
[TBL] [Abstract][Full Text] [Related]
12. Effect of regular intravenous immunoglobulin therapy on prevention of pneumonia in patients with common variable immunodeficiency.
Pourpak Z; Aghamohammadi A; Sedighipour L; Farhoudi A; Movahedi M; Gharagozlou M; Chavoshzadeh Z; Jadid L; Rezaei N; Moin M
J Microbiol Immunol Infect; 2006 Apr; 39(2):114-20. PubMed ID: 16604243
[TBL] [Abstract][Full Text] [Related]
13. Intravenous immunoglobulin (IVIg) for refractory and difficult-to-treat infections.
Ferrara G; Zumla A; Maeurer M
Am J Med; 2012 Oct; 125(10):1036.e1-8. PubMed ID: 22608788
[TBL] [Abstract][Full Text] [Related]
14. Intravenous immunoglobulin in the prevention and treatment of neonatal bacterial sepsis.
Lassiter HA
Adv Pediatr; 1992; 39():71-99. PubMed ID: 1442320
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic and therapeutic use of immunoglobulin for intravenous administration in patients with secondary immunodeficiencies associated with malignancies.
Morell A; Barandun S
Pediatr Infect Dis J; 1988 May; 7(5 Suppl):S87-91. PubMed ID: 2840630
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of intravenous immunoglobulin treatment in children with common variable immunodeficiency.
Baris S; Ercan H; Cagan HH; Ozen A; Karakoc-Aydiner E; Ozdemir C; Bahceciler NN
J Investig Allergol Clin Immunol; 2011; 21(7):514-21. PubMed ID: 22312934
[TBL] [Abstract][Full Text] [Related]
17. Increased risk of adverse events when changing intravenous immunoglobulin preparations.
Ameratunga R; Sinclair J; Kolbe J
Clin Exp Immunol; 2004 Apr; 136(1):111-3. PubMed ID: 15030521
[TBL] [Abstract][Full Text] [Related]
18. The potential impact of substitutive therapy with intravenous immunoglobulin on the outcome of heart transplant recipients with infections.
Carbone J; Sarmiento E; Palomo J; Fernandez-Yañez J; Muñoz P; Bouza E; Rodríguez-Molina J; Lanio N; Fernandez-Cruz E
Transplant Proc; 2007 Sep; 39(7):2385-8. PubMed ID: 17889198
[TBL] [Abstract][Full Text] [Related]
19. Treatment of epidermolysis bullosa acquisita with intravenous immunoglobulin in patients non-responsive to conventional therapy: clinical outcome and post-treatment long-term follow-up.
Ahmed AR; Gürcan HM
J Eur Acad Dermatol Venereol; 2012 Sep; 26(9):1074-83. PubMed ID: 21819451
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases.
Stein MR; Koterba A; Rodden L; Berger M
Postgrad Med; 2011 Sep; 123(5):186-93. PubMed ID: 21904101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
